|
|
Line 1: |
Line 1: |
| {{familytree/start}}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | | | | | | | | | | | | | A00 | |
| |
| A00=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Thymic Tumor, Resectable</div>}}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | | | | | | | | | | | | | |!| | | }}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | | | | | | | | | | | | | A01 | | | |
| |
| A01=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Pathology Evaluation</div>}}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | | | |,|-|-|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|-|-|.| | }}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | | | B01 | | | | | | | | B02 | | | | | | | | B03 | | |
| |
| B01=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">No Residual Tumor</div>|
| |
| B02=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Microscopic Residual Tumor</div>|
| |
| B03=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Macroscopic Residual Tumor</div>}}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | |,|-|^|-|.| | | | | |,|-|^|-|.| | | | | |,|-|^|-|.| | }}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | D01 | | D02 | | | | D03 | | D04 | | | | D05 | | D06 | |
| |
| D01=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Thymoma, no capsular invasion or thymic carcinoma, stage I</div>|
| |
| D02=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Thymoma or thymic carcinoma, capsular invasion present, stages II-IV</div>|
| |
| D03=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Thymoma</div>|
| |
| D04=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Thymic carcinoma</div>|
| |
| D05=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Thymoma</div>|
| |
| D06=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Thymic carcinoma</div>}}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | |!| | | |!| | | | | |!| | | |!| | | | | |!| | | |!| | | }}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | |!| | | E02 | | | | E03 | | E04 | | | | E05 | | E06 | | | |
| |
| E02=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Postoperative '''[[Thymoma treatment#Radiation Dose|RT]]'''</div>|
| |
| E03=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Postoperative '''[[Thymoma treatment#Radiation Dose|RT]]'''</div>|
| |
| E04=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Postoperative '''[[Thymoma treatment#Radiation Dose|RT]]''' + '''[[Thymoma treatment#Chemotherapy Regimens|Chemotherapy]]'''</div>|
| |
| E05=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">'''[[Thymoma treatment#Radiation Dose|RT]]''' ± '''[[Thymoma treatment#Chemotherapy Regimens|Chemotherapy]]'''</div>|
| |
| E06=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">'''[[Thymoma treatment#Radiation Dose|RT]]''' + '''[[Thymoma treatment#Chemotherapy Regimens|Chemotherapy]]'''</div>}}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | |!| | | |!| | | | | |!| | | |!| | | | | |!| | | |!| | | |}}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | |`|-|-|-|^|-|-|-|-|-|^|-|v|-|^|-|-|-|-|-|^|-|-|-|'| | | |}}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | | | | | | | | | | | | | |!| | | | | | | | | | | | | |}}
| |
| {{Family tree |border=2|boxstyle=background: WhiteSmoke; | | | | | | | | | | | | | F01 | | | | | | | | | | | | | |
| |
| F01=<div style="float: center; text-align: center; height: 2.5em; width: 120px; padding: 1em; font-size: 100%">Surveillance for recurrence with CT <BR> every 6 month for 2 y, then annually every 5 y for thymic carcinoma <BR> and 10 y for thymoma</div>}}
| |
| {{familytree/end}}
| |
|
| |
|
| ====Chemotherapy Regimens====
| |
|
| |
|
| <B><small>[[Thymoma treatment#Approach to Thymoma and Thymic Carcinoma|Return to top]]</small></B>
| | {|style="width:80%;" border=2 |
| | | | {{Sandbox/v31}} |
| {| {{table}} | |
| | align="center" style="background:#f0f0f0;" colspan=2|'''FIRST-LINE COMBINATION CHEMOTHERAPY REGIMENS'''
| |
| | align="center" style="background:#f0f0f0;"|'''SECOND-LINE CHEMOTHERAPY''' | |
| |-
| |
| | '''CAP''' (preferred for thymoma) <BR> * Cisplatin 50 mg/m² IV day 1 <BR> * Doxorubicin 50 mg/m² IV day 1 <BR> * Cyclophosphamide 500 mg/m² IV day 1 <BR> Administered every 3 weeks|| '''PE''' <BR> * Cisplatin 60 mg/m² IV day 1 <BR> *Etoposide 120 mg/m²/d IV days 1 -3 <BR> Administered every 3 weeks||rowspan=3 valign=top|Etoposide <BR> Ifosfamide <BR> Pemetrexed <BR> Octreotide (including LAR) + prednisone <BR> 5-FU and leucovirin <BR> Gemcitabine <BR> Paclitaxel
| |
| |-
| |
| | '''CAP with Prednisone''' <BR> * Cisplatin 30 mg/m² IV days 1-3 <BR> * Doxorubicin 20 mg/m²/d <BR> IV continuous infusion on days 1 to 3 <BR> * Cyclophosphamide 500 mg/m² IV on day 1 <BR> * Prednisone 100 mg/day on days 1-5 <BR> Administered every 3 weeks||'''VIP''' <BR> * Etoposide 75 mg/m² on days 1-4 <BR>* Ifosfamide 1.2 g/m² on days 1-4 <BR> * Cisplatin 20 mg/m² on days 1-4 <BR> Administered every 3 weeks
| |
| |-
| |
| | '''ADOC''' <BR> * Cisplatin 50 mg/m² IV day 1 <BR> * Doxorubicin 40 mg/m² IV day 1 <BR> * Vincristine 0.6 mg/m² IV day 3 <BR> * Cyclophosphamide 700 mg/m² IV day 4 <BR> Administered every 3 weeks || '''Carboplatin/Paclitaxel''' (preferred for Thymic Carcinoma) <BR>* Carboplatin AUC 6 <BR> * Paclitaxel 225 mg/m² <BR> Administered every 3 weeks
| |
| |-
| |
| |} | | |} |